Medinice has obtained the chronic phase preclinical study report for the CoolCryo project and thus completes the preclinical study for this CoolCryo project, the company announced. Medinice hopes to start clinical trials this year.
CoolCryo is a system for performing minimally invasive cardiac cryoablation. CoolCryo uses very low temperatures to destroy tissues. The system was designed specifically for cardiac ablation, which is ultimately to be performed using a minimally invasive technique with the use of videothoracic techniques, which is its major competitive advantage.
Currently, the second stage of preclinical studies of the chronic phase on animals has been successfully completed.
“Recently, the console and the applicator itself have been rebuilt, now we checked the ergonomics, i.e. the ease of inserting and operating the applicator. The effects of ablation were also checked immediately after the procedure and after the agreed observation time,” said Grzegorz Wróblewski, director of technology at Medinice, quoted in the release.
The cryoapplicator is to be used for full-thickness ablation, performed with a minimally invasive technique, which is its great competitive advantage. On the other hand, the use of liquid nitrogen significantly reduces the cost of the procedure, the company emphasized.
Medinice is a Polish company with a global reach, which is a platform for solutions used in cardiology. The company develops its own projects and projects obtained from scientists from Poland and abroad. The team consists of professionals in the field of medicine, clinical trials, law (in particular intellectual property) and finance. The company debuted on the main market of the Warsaw Stock Exchange in 2020.